marburg virus disease

Summary

Summary: An RNA virus infection of rhesus, vervet, and squirrel monkeys transmissible to man.

Top Publications

  1. Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology. 2003;314:350-7 pubmed
    ..These data suggest that neutralizing epitopes exist within MBGV GP but that induction of antibodies to these neutralizing epitopes may not be sufficient for protection from lethal infection...
  2. Fisher Hoch S. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull. 2005;73-74:123-37 pubmed
    ..Educating the public to demand higher standards could be a powerful tool. Good practices are difficult to establish and maintain on the scale needed...
  3. Feldmann H. Marburg hemorrhagic fever--the forgotten cousin strikes. N Engl J Med. 2006;355:866-9 pubmed
  4. Carrion R, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, et al. A small nonhuman primate model for filovirus-induced disease. Virology. 2011;420:117-24 pubmed publisher
    ..Lymphoid necrosis and lymphocytic depletion observed in spleen. These findings provide support for the use of the common marmoset as a small nonhuman primate model for filovirus induced hemorrhagic fever...
  5. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003;21:4071-80 pubmed
  6. Monath T. Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis. 1999;179 Suppl 1:S127-38 pubmed
    ..Such viruses may have separate life cycles or may give rise to virulent strains by mutation...
  7. Lofts L, Ibrahim M, Negley D, Hevey M, Schmaljohn A. Genomic differences between guinea pig lethal and nonlethal Marburg virus variants. J Infect Dis. 2007;196 Suppl 2:S305-12 pubmed
    ..The L gene mutations were equally intriguing, clustering near a highly conserved motif in viral RNA-dependent RNA polymerases. ..
  8. Daddario DiCaprio K, Geisbert T, Stroher U, Geisbert J, Grolla A, Fritz E, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006;367:1399-404 pubmed
    ..Indeed, these data suggest that rVSV-based filoviral vaccines might not only have potential as preventive vaccines, but also could be equally useful for postexposure treatment of filoviral infections. ..
  9. Colebunders R, Tshomba A, Van Kerkhove M, Bausch D, Campbell P, Libande M, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis. 2007;196 Suppl 2:S148-53 pubmed
    ..Treatment in isolation wards was acceptable, but the quality of clinical documentation was unsatisfactory. Improved clinical documentation is necessary for a basic evaluation of supportive treatment. ..

More Information

Publications81

  1. Weidmann M, Mühlberger E, Hufert F. Rapid detection protocol for filoviruses. J Clin Virol. 2004;30:94-9 pubmed
    ..All three assays were highly sensitive and specific. The mobility of the assay system may help to contain future outbreaks. ..
  2. Basler C, Amarasinghe G. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res. 2009;29:511-20 pubmed publisher
    ..Thus, despite their similarities, there are fundamental differences by which these deadly viruses counteract the IFN system. It will be of interest to determine how these differences influence pathogenesis. ..
  3. Geisbert T, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204 Suppl 3:S1075-81 pubmed publisher
    ..Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections. ..
  4. Bertherat E, Talarmin A, Zeller H. [Democratic Republic of the Congo: between civil war and the Marburg virus. International Committee of Technical and Scientific Coordination of the Durba Epidemic]. Med Trop (Mars). 1999;59:201-4 pubmed
    ..When an epidemic of Marburg virus disease occurred in the Durba region located in the northeastern part of the People's Republic of the Congo, 23 ..
  5. Kortepeter M, Bausch D, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204 Suppl 3:S810-6 pubmed publisher
    ..By identifying key unanswered questions and gaps in clinical data, it will help guide clinical research in future outbreaks...
  6. Grant Klein R, Altamura L, Schmaljohn C. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Virus Res. 2011;162:148-61 pubmed publisher
    ..In this review, we consider the status of various recombinant DNA candidate vaccines against Lassa virus and filoviruses which have been tested in animals. ..
  7. Alves D, Glynn A, Steele K, Lackemeyer M, Garza N, Buck J, et al. Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. Vet Pathol. 2010;47:831-51 pubmed publisher
    ..These macaques exhibited a number of features similar to those of human filovirus infections; as such, this model of aerosolized MARV-Angola might be useful in developing medical countermeasures under the Animal Rule. ..
  8. Borchert M, Mulangu S, Swanepoel R, Libande M, Tshomba A, Kulidri A, et al. Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis. 2006;12:433-9 pubmed
    ..The secondary attack risk was 21%; the postintervention reproduction number was 0.9, consistent with an outbreak sustained by repeated primary transmission, rather than large-scale secondary transmission. ..
  9. Kolesnikova L, Bugany H, Klenk H, Becker S. VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. J Virol. 2002;76:1825-38 pubmed
    ..Our data indicate that MBGV VP40 was able to interact with membranes of late endosomes in the course of viral infection. This capability was independent of other MBGV proteins. ..
  10. Geisbert T, Jaax N. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol. 1998;22:3-17 pubmed
    ..This case demonstrates the value of transmission electron microscopy as a tool for assisting in the definitive diagnosis of Marburg or Ebola hemorrhagic fever, as well as providing insight into the pathogenesis of these agents. ..
  11. Bradfute S, Warfield K, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol. 2008;180:4058-66 pubmed
    ..These findings should cause a change in the current view of the 'impaired' immune response to EBOV challenge and may help spark new therapeutic strategies to control lethal filovirus disease. ..
  12. Bausch D, Borchert M, Grein T, Roth C, Swanepoel R, Libande M, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis. 2003;9:1531-7 pubmed
    ..Secondary transmission appears to be less common with Marburg virus than with Ebola virus, the other known filovirus. ..
  13. Grolla A, Lucht A, Dick D, Strong J, Feldmann H. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot. 2005;98:205-9 pubmed
    ..In addition, the role of field-based laboratory support and its limitations and capabilities in an outbreak response setting, especially in regards to real-time PCR and immunofiltration assays, is presented...
  14. Geisbert T, Bailey M, Geisbert J, Asiedu C, Roederer M, Grazia Pau M, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol. 2010;84:10386-94 pubmed publisher
  15. Bente D, Gren J, Strong J, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech. 2009;2:12-7 pubmed publisher
  16. Hensley L, Alves D, Geisbert J, Fritz E, Reed C, Larsen T, et al. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J Infect Dis. 2011;204 Suppl 3:S1021-31 pubmed publisher
    ..In this study we evaluated the progression of MARV infection in nonhuman primates...
  17. Warfield K, Alves D, Bradfute S, Reed D, VanTongeren S, Kalina W, et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J. 2007;4:108 pubmed
    ..Also, as shown here, the scid-adapted MARV mouse models can be used to evaluate the efficacy of candidate antiviral therapeutic molecules, such as phosphorodiamidate morpholino oligomers or antibodies...
  18. Leroy E, Baize S, Gonzalez J. [Ebola and Marburg hemorrhagic fever viruses: update on filoviruses]. Med Trop (Mars). 2011;71:111-21 pubmed
    ..The purpose of this review is to present the main developments in these particular fields in the last decade...
  19. Ramanan P, Shabman R, Brown C, Amarasinghe G, Basler C, Leung D. Filoviral immune evasion mechanisms. Viruses. 2011;3:1634-49 pubmed publisher
    ..The examples also represent distinct mechanisms utilized by filoviral proteins in order to counter immune responses, which results in limited IFN-?/? production and downstream signaling...
  20. Warren T, Warfield K, Wells J, Enterlein S, Smith M, Ruthel G, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother. 2010;54:2152-9 pubmed publisher
    ..Taken together, these results identify a promising antiviral therapeutic candidate for the treatment of filovirus infections...
  21. Amman B, Carroll S, Reed Z, Sealy T, Balinandi S, Swanepoel R, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog. 2012;8:e1002877 pubmed publisher
    ..aegyptiacus bats existing as a large meta-population with associated virus circulation over broad geographic ranges. These findings provide a basis for developing Marburg hemorrhagic fever risk reduction strategies...
  22. MacNeil A, Rollin P. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases?. PLoS Negl Trop Dis. 2012;6:e1546 pubmed publisher
  23. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003;57:53-60 pubmed
    ..Terrorists might have great difficulty acquiring a filovirus for use as a weapon, but my attempt to do so because of the agents' ability to inspire fear. Accurate information is the best tool to prevent panic in the event of an attack...
  24. van Paassen J, Bauer M, Arbous M, Visser L, Schmidt Chanasit J, Schilling S, et al. Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis. 2012;12:635-42 pubmed publisher
    ..Aggressive critical-care treatment with renal replacement therapy and use of the molecular absorbent recirculation system appeared able to stabilise--at least temporarily--the patient's condition...
  25. Kalina W, Warfield K, Olinger G, Bavari S. Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virol J. 2009;6:132 pubmed publisher
    ..In our study, we infected BALB/c mice with plaque-purified, nonlethal MARV and used overlapping peptides to map H2d-restricted CD8+ T-cell epitopes...
  26. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487-98 pubmed
    ..Recent studies in non-human primates have shown that blocking of certain host responses, such as the coagulation cascade, can result in reduced viral replication and improved host survival...
  27. Ligon B. Outbreak of Marburg hemorrhagic fever in Angola: a review of the history of the disease and its biological aspects. Semin Pediatr Infect Dis. 2005;16:219-24 pubmed
    ..This article reviews the history of the disease caused by Marburg virus and its biological components...
  28. Roddy P, Thomas S, Jeffs B, Nascimento Folo P, Pablo Palma P, Moco Henrique B, et al. Factors associated with Marburg hemorrhagic fever: analysis of patient data from Uige, Angola. J Infect Dis. 2010;201:1909-18 pubmed publisher
    ..Continued efforts to improve clinical documentation during filovirus outbreaks would aid in the refinement of case definitions and facilitate outbreak control. ..
  29. Swenson D, Warfield K, Larsen T, Alves D, Coberley S, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines. 2008;7:417-29 pubmed publisher
    ..Guinea pigs vaccinated with Marburg virus VLPs (mVLPs) or inactivated MARV (iMARV) develop homologous humoral and T-cell responses and are completely protected from a lethal homologous MARV challenge...
  30. Hartman A, Towner J, Nichol S. Ebola and marburg hemorrhagic fever. Clin Lab Med. 2010;30:161-77 pubmed publisher
  31. Böckeler M, Stroher U, Seebach J, Afanasieva T, Suttorp N, Feldmann H, et al. Breakdown of paraendothelial barrier function during Marburg virus infection is associated with early tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1. J Infect Dis. 2007;196 Suppl 2:S337-46 pubmed
  32. Slenczka W, Klenk H. Forty years of marburg virus. J Infect Dis. 2007;196 Suppl 2:S131-5 pubmed
    ..Marburg was not the only town where the virus was isolated and identified for the first time, but most cases of infection occurred in Marburg...
  33. Grolla A, Jones S, Fernando L, Strong J, Stroher U, Möller P, et al. The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis. 2011;5:e1183 pubmed publisher
    ..Marburg virus (MARV), a zoonotic pathogen causing severe hemorrhagic fever in man, has emerged in Angola resulting in the largest outbreak of Marburg hemorrhagic fever (MHF) with the highest case fatality rate to date...
  34. Peterson A, Lash R, Carroll D, Johnson K. Geographic potential for outbreaks of Marburg hemorrhagic fever. Am J Trop Med Hyg. 2006;75:9-15 pubmed
    ..Overall, results demonstrate that ecologic niche modeling can be a powerful tool in understanding geographic distributions of species and other biologic phenomena such as zoonotic disease transmission from natural reservoir populations...
  35. Wang D, Hevey M, Juompan L, Trubey C, Raja N, Deitz S, et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology. 2006;353:324-32 pubmed
    ..Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV...
  36. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis. 2011;204 Suppl 3:S986-90 pubmed publisher
    ..A virus-like particle vaccine elicited strong antibody responses but did not protect against mouse-adapted ZEBOV challenge...
  37. Geisbert T, Daddario DiCaprio K, Geisbert J, Young H, Formenty P, Fritz E, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis. 2007;196 Suppl 2:S372-81 pubmed
  38. Bausch D, Nichol S, Muyembe Tamfum J, Borchert M, Rollin P, Sleurs H, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med. 2006;355:909-19 pubmed
    ..An outbreak of Marburg hemorrhagic fever was first observed in a gold-mining village in northeastern Democratic Republic of the Congo in October 1998...
  39. Wang D, Schmaljohn A, Raja N, Trubey C, Juompan L, Luo M, et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006;24:2975-86 pubmed
    ..These promising results indicate that a cAdVax-based vaccine could be effective for induction of both humoral and cell-mediated immune responses to multiple strains of the Marburg virus...
  40. Leroy E, Gonzalez J, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-76 pubmed publisher
    ..As a result, our understanding of the ecology, host interactions, and control of these viruses has improved considerably...
  41. Hart M. Vaccine research efforts for filoviruses. Int J Parasitol. 2003;33:583-95 pubmed
    ..The vaccine approaches discussed include DNA-based vaccines, and subunit vaccines vectored by adenovirus, alphavirus replicons, and vaccinia virus...
  42. Roddy P, Weatherill D, Jeffs B, Abaakouk Z, Dorion C, Rodriguez Martinez J, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community. J Infect Dis. 2007;196 Suppl 2:S162-7 pubmed
    ..Actively involving all stakeholders from the start of the outbreak response is crucial...
  43. Carette J, Raaben M, Wong A, Herbert A, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340-3 pubmed publisher
    ..Our findings uncover unique features of the entry pathway used by filoviruses and indicate potential antiviral strategies to combat these deadly agents...
  44. Enterlein S, Volchkov V, Weik M, Kolesnikova L, Volchkova V, Klenk H, et al. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol. 2006;80:1038-43 pubmed publisher
    ..In contrast, rescue of recombinant EBOV was not supported by EBOV VP30 containing a mutated Zn-binding domain...
  45. Warfield K, Bradfute S, Wells J, Lofts L, Cooper M, Alves D, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009;83:6404-15 pubmed publisher
    ..This mouse-adapted MARV strain can now be used to develop and evaluate novel vaccines and therapeutics and may also help to provide a better understanding of the virulence factors associated with MARV...
  46. Warfield K, Olinger G. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol. 2011;2011:984241 pubmed publisher
    ..Advancements in assays and technologies may allow these studies to occur during future outbreaks...
  47. Daddario DiCaprio K, Geisbert T, Geisbert J, Stroher U, Hensley L, Grolla A, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. 2006;80:9659-66 pubmed
    ..These data suggest that the VSVDeltaG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains...
  48. Towner J, Pourrut X, Albarino C, Nkogue C, Bird B, Grard G, et al. Marburg virus infection detected in a common African bat. PLoS ONE. 2007;2:e764 pubmed
    ..These data imply that more areas are at risk for MHF outbreaks than previously realized and correspond well with a recently published report in which three species of fruit bats were demonstrated to be likely reservoirs for Ebola virus...
  49. Saijo M, Georges Courbot M, Fukushi S, Mizutani T, Philippe M, Georges A, et al. Marburgvirus nucleoprotein-capture enzyme-linked immunosorbent assay using monoclonal antibodies to recombinant nucleoprotein: detection of authentic Marburgvirus. Jpn J Infect Dis. 2006;59:323-5 pubmed
    ..These results suggest that the Ag-capture ELISA using the monoclonal antibodies, 2A7 and 2H6, is applicable to the diagnosis of MHF...
  50. Fritz E, Geisbert J, Geisbert T, Hensley L, Reed D. Cellular immune response to Marburg virus infection in cynomolgus macaques. Viral Immunol. 2008;21:355-63 pubmed publisher
    ..IL-6 production was detected late in the infection in CD14(+) spleen cells. These results suggest a robust innate immune response to MARV; however, this response was delayed relative to the infection...
  51. Maganga G, Bourgarel M, Ella G, Drexler J, Gonzalez J, Drosten C, et al. Is Marburg virus enzootic in Gabon?. J Infect Dis. 2011;204 Suppl 3:S800-3 pubmed publisher
  52. Geisbert T, Hensley L, Geisbert J, Leung A, Johnson J, Grolla A, et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis. 2010;16:1119-22 pubmed publisher
    ..We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection...
  53. Warren T, Warfield K, Wells J, Swenson D, Donner K, Van Tongeren S, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991-4 pubmed publisher
    ..PMOplus may be useful for treating these and other highly pathogenic viruses in humans...
  54. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998;251:28-37 pubmed
    ..Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease...
  55. Geisbert T, Bausch D, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol. 2010;20:344-57 pubmed publisher
    ..The rVSV-based vaccine has also shown utility when administered for postexposure prophylaxis against filovirus infections. A VSV-based Ebola vaccine was recently used to manage a potential laboratory exposure. ..
  56. Timen A, Koopmans M, Vossen A, van Doornum G, Gunther S, van den Berkmortel F, et al. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis. 2009;15:1171-5 pubmed publisher
    ..We present lessons learned and results of the follow-up serosurvey of contacts and focus on factors that prevented overreaction during an event with a high public health impact...
  57. Lofts L, Wells J, Bavari S, Warfield K. Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process. J Virol. 2011;85:3905-17 pubmed publisher
    ..These studies provide insights into how marburgviruses manipulate the host for enzymes, metabolites, translation regulators, and effectors of the innate immune response to serve as potential viral countermeasures...
  58. Swenson D, Wang D, Luo M, Warfield K, Woraratanadharm J, Holman D, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol. 2008;15:460-7 pubmed publisher
    ..This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack...
  59. Warfield K, Posten N, Swenson D, Olinger G, Esposito D, Gillette W, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007;196 Suppl 2:S421-9 pubmed
    ..The goal of this work was to increase the yield of VLPs, while retaining their immunogenic properties...
  60. Towner J, Khristova M, Sealy T, Vincent M, Erickson B, Bawiec D, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol. 2006;80:6497-516 pubmed publisher
    ..This is in contrast to the 1998 to 2000 marburgvirus outbreak, where evidence of several virus genetic lineages (with up to 21% divergence) and multiple virus introductions into the human population was found...
  61. Kurosaki Y, Grolla A, Fukuma A, Feldmann H, Yasuda J. Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J Clin Microbiol. 2010;48:2330-6 pubmed publisher
    ..Furthermore, it seems suitable for use for field diagnostics or in laboratories in areas where MARV is endemic...
  62. Lever M, Piercy T, Steward J, Eastaugh L, Smither S, Taylor C, et al. Lethality and pathogenesis of airborne infection with filoviruses in A129 ?/? -/- interferon receptor-deficient mice. J Med Microbiol. 2012;61:8-15 pubmed publisher
    ..The KO mouse may provide a useful model to test potential antiviral therapeutics against wild-type filoviruses...
  63. Borchert M, Muyembe Tamfum J, Colebunders R, Libande M, Sabue M, Van der Stuyft P. Short communication: a cluster of Marburg virus disease involving an infant. Trop Med Int Health. 2002;7:902-6 pubmed
    ..The findings show that mild cases of MHF have to be expected during an outbreak and point out the difficulty to base patient management decisions on clinical case definitions alone...
  64. Towner J, Amman B, Sealy T, Carroll S, Comer J, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 2009;5:e1000536 pubmed publisher
    ..These data indicate common Egyptian fruit bats can represent a major natural reservoir and source of Marburg virus with potential for spillover into humans...
  65. Geisbert T, Geisbert J, Leung A, Daddario DiCaprio K, Hensley L, Grolla A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296-304 pubmed publisher
    ..In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species...
  66. Adjemian J, Farnon E, Tschioko F, Wamala J, Byaruhanga E, Bwire G, et al. Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis. 2011;204 Suppl 3:S796-9 pubmed publisher
    ..We describe the epidemiologic investigation and the health education response...
  67. Bausch D, Sprecher A, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. 2008;78:150-61 pubmed publisher
    ..Here, we review the present research priorities and environment for field study of the filovirus hemorrhagic fevers and outline a strategy for future prospective clinical research on treatment and vaccine prevention...
  68. Jeffs B, Roddy P, Weatherill D, de la Rosa O, Dorion C, Iscla M, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital. J Infect Dis. 2007;196 Suppl 2:S154-61 pubmed
    ..More interventional medical care may not only improve survival but also improve acceptability...
  69. Geisbert T, Daddario DiCaprio K, Geisbert J, Reed D, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894-900 pubmed publisher
    ..Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection...
  70. Saijo M, Niikura M, Morikawa S, Ksiazek T, Meyer R, Peters C, et al. Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins. J Clin Microbiol. 2001;39:1-7 pubmed publisher
    ..The results indicate that ELISA systems prepared with the recombinant NPs of EBO and MBG are valuable tools for the diagnosis of EBO and MBG infections and for seroepidemiological field studies...
  71. Valmas C, Grosch M, Schumann M, Olejnik J, Martinez O, Best S, et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010;6:e1000721 pubmed publisher
    ..It identifies a novel function for the MARV VP40 protein and suggests that MARV may globally inhibit Jak1-dependent cytokine signaling...
  72. Falzarano D, Geisbert T, Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines. 2011;10:63-77 pubmed publisher
    ..These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use. ..